BioDelivery Sciences International (Nasdaq: BDSI) has won regulatory approval to expand its product footprint.
The Raleigh-based firm on Monday said its “breakthrough pain treatment” for cancer patients has received regulatory approval in Taiwan.
TTY Biopharm licensed BDSU’s Onsolis and will sell the drug there under the name Painkyl.
BDSI will receive a $300,000 milestone payment and royalties on future sales.
Onsolis already is sold in the U.S. and Canada as well as the European Union.
